updat model re-affirmed bull thesi post result
reiter buy rate pt updat model
result continu believ thesi high visibl double-digit ep
growth help capit deploy q/q nois surround near
term book bill trend tuck-in impact us continu benefit
solid industri backdrop high revenu visibl oper leverag
see ebitda grow sale excel convers
aggress redeploy capit toward repurchas see recent share
weak fda news buy opportun link
respond link fda press releas link confirm strh initi
thought link subsequ press releas fda confirm
note convers issu impact wide use inform
market research servic methodolog provid
intern process alreadi identifi issu prior fda notif
client notifi back april year step
alreadi taken rectifi convers issu
sight doubl digit ep growth reiter pt
support proprietari repurchas model workabl model avail
compound-annual-growth-rate rang vs repurchas
model updat see chang ep ep crimp
fine tune model digest result see littl chang
prior ep estim model
revenu respect larg flow ep remain
unchang upper end re-affirmed
guidanc believ justifi given aggress repurchas
includ announc repo announc secondari
lower ep estim primarili due
conserv view oper expens impact off-set
benefit improv gross margin profil
pt pt impli price-to-earnings multipl ep estim
ahead ahead impli consensu price-to-earnings justifi
expect repurchas effort think contempl street
well valuat consider use broader peer group
mainli flow impact
conserv remain quarter
ad bp prior gm assumpt
conservat way impact
tr target
revenu depict prior year adjust
account rule
consensu estim may blend
account rule may compar strh
scenario overview capit redeploy model construct use guidanc
broader commentari long term growth capit redeploy strategi
low- mid- high- case scenario
assum organ grower
tuck-in drive upsid top line growth
expect ebitda grow around revenu growth
annual capit deploy equat ad net incom
amount alloc toward repurchas balanc toward
scenario rang impli low- high- ep compound-annual-growth-rate rang
workabl copi model avail client upon request
pt approxim sensit tabl examin impli valuat base
low- high- ep rang price-to-earnings rang comp page respect
page
strh highlowmid highorgan growth revenu growth margin bp bpsadj net growth deploy price share year wa zero share factset strh scenario ep factset strh research ia hold inc
valuat rang assumpt low- mid- high case page
base follow consider
averag ntm price-to-earnings multipl cro peer group well would view
multipl valuat ascrib under-perform cro assign low- case
mid- case consid valuat multipl believ accur reflect
iqv abil drive mid- high- teen ep growth well consider receiv
premium highli visibl high margin im data busi attribut
reflect mid-cap technolog servic compani
high-cas contempl valuat multipl assum receiv
credit uniqu data asset get treat market technolog servic
compani rather tradit cro
page
nametickerratingpricemktcaprevenueebitdaepspegmid-cap technolog design system system group inc class payment inc class analyt river laboratori inc class carequest diagnost corpor america group boot allianc factset strh multipl ia hold inc
page
share upsid current strh scenariovaluationstrh pt low/high rangesourc factset strh research iqvia hold inc
page
sandi draper statement dollar servic y/i total gross depreci restructur merger impair oper fit incl restruc net interest expens incom incom incom tax tax equiti unconsolid equiti earn unconsolid net net loss incom attribut non-controlling net incom attribut dilut dilut share forma adjust net adj pre-tax tax non-gaap net non-gaap ep onward recast growth forma adjust ebitdaadjust ebitda onward recast margin margin robinson humphrey research estimatestick iqva
iqvia largest cro revenu oper countri employe
compani found headquart durham nc compani formerli quintil
merg im health combin entiti iqvia oper three segment commerci
solut data technolog drive real world evid use life sceinc client clinic
trial integr healthcar servic contract sale compris
respect sale iqvia first went public taken privat privat equiti
went public acquird im health
buy rate base view ebitda growth exceed revenu growth due
oper leverag cost synergi recognit expect manag reinforc oper
perform share repurchas expect contribut mid-teen ep growth
also think acquir im busi may benefit multipl expans mid-cap peer
technolog servic space given acquisit im
valuat risk
pt assign probabl low case price-to-earnings stock mid case
price-to-earnings stock high case price-to-earnings stock pt impli
price-to-earnings multipl ep estim ahead ahead impli consensu price-to-earnings
justifi expect repurchas effort think contempl street well
valuat consider use broader peer group
risk rate price target
continu cancel late stage busi net book bill remain target
merger synergi fail materi custom attrit due im merger
sandi draper herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
